5-(4-BROMO-PHENYL)-1-METHYL-1H-IMIDAZOL-2-YLAMINE
![]() |
- $160 - $1333
- Product name: 5-(4-BROMO-PHENYL)-1-METHYL-1H-IMIDAZOL-2-YLAMINE
- CAS: 787586-84-9
- MF: C10H10BrN3
- MW: 252.11
- EINECS:
- MDL Number:MFCD05668691
- Synonyms:5-(4-BROMO-PHENYL)-1-METHYL-1H-IMIDAZOL-2-YLAMINE
4 prices
Selected condition:
Brand
- Absolute Chiral
- American Custom Chemicals Corporation
- Crysdot
- Labseeker
Package
- 100mg
- 1G
- ManufacturerAbsolute Chiral
- Product numberD1268-00-N
- Product description5-(4-Bromophenyl)-1-methyl-1H-imidazol-2-ylamine 95%
- Packaging100mg
- Price$160
- Updated2021-12-16
- Buy
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberHCH0047592
- Product description5-(4-BROMO-PHENYL)-1-METHYL-1H-IMIDAZOL-2-YLAMINE 95.00%
- Packaging1G
- Price$1280.66
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11056785
- Product description5-(4-Bromophenyl)-1-methyl-1H-imidazol-2-amine 97%
- Packaging1g
- Price$550
- Updated2021-12-16
- Buy
- ManufacturerLabseeker
- Product numberSC-31761
- Product description5-(4-BROMO-PHENYL)-1-METHYL-1H-IMIDAZOL-2-YLAMINE 95
- Packaging1g
- Price$1333
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Absolute Chiral | D1268-00-N | 5-(4-Bromophenyl)-1-methyl-1H-imidazol-2-ylamine 95% | 100mg | $160 | 2021-12-16 | Buy |
American Custom Chemicals Corporation | HCH0047592 | 5-(4-BROMO-PHENYL)-1-METHYL-1H-IMIDAZOL-2-YLAMINE 95.00% | 1G | $1280.66 | 2021-12-16 | Buy |
Crysdot | CD11056785 | 5-(4-Bromophenyl)-1-methyl-1H-imidazol-2-amine 97% | 1g | $550 | 2021-12-16 | Buy |
Labseeker | SC-31761 | 5-(4-BROMO-PHENYL)-1-METHYL-1H-IMIDAZOL-2-YLAMINE 95 | 1g | $1333 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|